QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=939235184CEB0A4FED235F93FAB59041;jsessionid=863A4C9889D16F68A1145EAA8E447BDE;jsessionid=2ACE7F9703D923EDCF763AB1F8370A7A;jsessionid=49D26FD2B5335FA78FE737A7A7456B7B;jsessionid=74557F0BF4D8F3C13915D5A8456B5643;jsessionid=E5B0346598E01D5F0E82722AD84F9F82;jsessionid=4DA6D8800C9562134B43E894BB39E935 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=939235184CEB0A4FED235F93FAB59041;jsessionid=863A4C9889D16F68A1145EAA8E447BDE;jsessionid=2ACE7F9703D923EDCF763AB1F8370A7A;jsessionid=49D26FD2B5335FA78FE737A7A7456B7B;jsessionid=74557F0BF4D8F3C13915D5A8456B5643;jsessionid=E5B0346598E01D5F0E82722AD84F9F82;jsessionid=4DA6D8800C9562134B43E894BB39E935